24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma ...

Dupixent’s Growth Story Dupixent continues to be Regeneron’s primary growth driver, with global net sales reaching $3.7 billion in Q1 2025, representing 20% year-over-year growth.

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach ...

Dupixent (dupilumab) made more than €5 billion last year from its current uses in atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps, and EoE is one of a clutch ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

Natalia included her late father's iconic Nike sheath logo at the top, hovering right on her heart. Natalia graduated from USC's School of Cinematic Arts. Congratulations poured in from USC women ...

Taurasi began using Dupixent, and it has helped her keep her eczema under control. “I was unfamiliar with the companies and with the medicine,” She said. “And as I got more familiar with ...

You know it’s a “slow news day” when people start talking about color schemes for logos over just about anything else that’s going on in the gaming world. Yet, here we are. As we reported ...

What was a commonly known secret finally became official Wednesday when the Utah Hockey Club unveiled its new nickname, the Mammoth, and its logo. Last week, the Utah Mammoth name was shown on the ...

A GSK drug that targets a pathway behind the lung inflammation in chronic obstructive pulmonary disease, or COPD, has won a long-awaited FDA approval, positioning the biologic medicine to reach ...